Cargando…

Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition)

OBJECTIVE: To explore the safety of the essential medicines recorded in China's list through the comparison of the list of essential medicines of China and the World Health Organization (WHO), as well as the analysis of the basic situation and characteristics of adverse drug reactions (ADRs) on...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Fangfang, Chen, Hongdou, Chen, Yanfang, Ye, Lu, Wu, Huanhuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015697/
https://www.ncbi.nlm.nih.gov/pubmed/29984248
http://dx.doi.org/10.1155/2018/7862306
_version_ 1783334454466445312
author Zheng, Fangfang
Chen, Hongdou
Chen, Yanfang
Ye, Lu
Wu, Huanhuan
author_facet Zheng, Fangfang
Chen, Hongdou
Chen, Yanfang
Ye, Lu
Wu, Huanhuan
author_sort Zheng, Fangfang
collection PubMed
description OBJECTIVE: To explore the safety of the essential medicines recorded in China's list through the comparison of the list of essential medicines of China and the World Health Organization (WHO), as well as the analysis of the basic situation and characteristics of adverse drug reactions (ADRs) on the two essential medicines recorded in China's and WHO lists in order to provide a reference for the improvement of China's list. METHODS: A retrospective descriptive study was conducted, based on the database in Jiangsu Province ADR Monitoring Center from 2013 to 2015. A total of 266869 cases reports were collected within this period, comparing the differences between the two essential medicines recorded in China's and WHO lists, considering number of ADRs, type of report, and modes of administration. Compare the differences between the two groups of drugs in the presence of new, severe, and new severe adverse events using chi square test. RESULTS: Comparing the two essential medicines list, they have the same 117 species. When comparing ADRs in the two groups, most are antimicrobial, electrolytes, and acid-base balance drugs, regulate water, and are higher in China. In addition, with respect to the number of ADR types in the two groups, there is statistical significance (p<0.001) (total number is 68603 and 47515, new types are 12601 and 7262, the severe are 2714 and 7566, and the new severe are 820 and 716). CONCLUSION: Compared to the WHO list of essential drugs, China's list is still to be improved.
format Online
Article
Text
id pubmed-6015697
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-60156972018-07-08 Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition) Zheng, Fangfang Chen, Hongdou Chen, Yanfang Ye, Lu Wu, Huanhuan Biomed Res Int Review Article OBJECTIVE: To explore the safety of the essential medicines recorded in China's list through the comparison of the list of essential medicines of China and the World Health Organization (WHO), as well as the analysis of the basic situation and characteristics of adverse drug reactions (ADRs) on the two essential medicines recorded in China's and WHO lists in order to provide a reference for the improvement of China's list. METHODS: A retrospective descriptive study was conducted, based on the database in Jiangsu Province ADR Monitoring Center from 2013 to 2015. A total of 266869 cases reports were collected within this period, comparing the differences between the two essential medicines recorded in China's and WHO lists, considering number of ADRs, type of report, and modes of administration. Compare the differences between the two groups of drugs in the presence of new, severe, and new severe adverse events using chi square test. RESULTS: Comparing the two essential medicines list, they have the same 117 species. When comparing ADRs in the two groups, most are antimicrobial, electrolytes, and acid-base balance drugs, regulate water, and are higher in China. In addition, with respect to the number of ADR types in the two groups, there is statistical significance (p<0.001) (total number is 68603 and 47515, new types are 12601 and 7262, the severe are 2714 and 7566, and the new severe are 820 and 716). CONCLUSION: Compared to the WHO list of essential drugs, China's list is still to be improved. Hindawi 2018-06-10 /pmc/articles/PMC6015697/ /pubmed/29984248 http://dx.doi.org/10.1155/2018/7862306 Text en Copyright © 2018 Fangfang Zheng et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Zheng, Fangfang
Chen, Hongdou
Chen, Yanfang
Ye, Lu
Wu, Huanhuan
Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition)
title Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition)
title_full Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition)
title_fullStr Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition)
title_full_unstemmed Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition)
title_short Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition)
title_sort comparative analysis of adr on china's national essential medicines list (2015 edition) and who model list of essential medicines (19th edition)
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015697/
https://www.ncbi.nlm.nih.gov/pubmed/29984248
http://dx.doi.org/10.1155/2018/7862306
work_keys_str_mv AT zhengfangfang comparativeanalysisofadronchinasnationalessentialmedicineslist2015editionandwhomodellistofessentialmedicines19thedition
AT chenhongdou comparativeanalysisofadronchinasnationalessentialmedicineslist2015editionandwhomodellistofessentialmedicines19thedition
AT chenyanfang comparativeanalysisofadronchinasnationalessentialmedicineslist2015editionandwhomodellistofessentialmedicines19thedition
AT yelu comparativeanalysisofadronchinasnationalessentialmedicineslist2015editionandwhomodellistofessentialmedicines19thedition
AT wuhuanhuan comparativeanalysisofadronchinasnationalessentialmedicineslist2015editionandwhomodellistofessentialmedicines19thedition